The amyloid precursor protein (APP) is not only processed to the neurotoxic amyloid-b peptide but also to various types of secreted APP variants. In a recent issue of Science, Rice et al. (2019) now demonstrate that secreted APP functions as a modulator of synaptic transmission by binding to GABA B R1a.
More than 30 years ago, the Beyreuther lab identified and cloned the gene-encoding amyloid-b peptide (Ab), the major building block of the Alzheimer's disease (AD) characteristic amyloid plaques. Cloning revealed a surprising result, namely that Ab must be generated by proteolytic processing from a much larger protein, the amyloid precursor protein (Haass and Selkoe, 2007) . During the last decade, APP processing was investigated in great detail, and several different pathways were identified (M€ uller et al., 2017) ( Figure 1A) . To produce Ab, the precursor is first cleaved by b-secretase within its ectodomain. This releases sAPP-b and generates a membraneretained C-terminal fragment (CTF-b). CTF-b is than cleaved by g-secretase, which finally releases Ab into the extracellular space and the amyloid precursor protein (APP) intracellular domain (AICD) into the cytoplasm. In a parallel competing non-amyloidogenic pathway, APP is cleaved by either a-secretase or h-secretase to release two additional variants of the APP ectodomain, namely sAPP-a and sAPP-h. (M€ uller et al., 2017; Willem et al., 2015) . The resulting CTF-a is also cleaved by g-secretase to produce a truncated version of Ab called p3. CTF-h is further processed by aor b-secretase in a competitive manner to liberate the non-amyloidgenic Ah-a and Ah-b (Willem et al., 2015) . Furthermore, additional proteases, such as Meprin-b, and caspases have also been implicated in other minor APP processing pathways (M€ uller et al., 2017) . APP processing is therefore quite complex and produces a large number of different cleavage products with probably very divergent functions. APP, as the precursor for the generation of the neurotoxic Ab, is a major therapeutic drug target, and understanding the physiological and pathological function of each processing product is therefore of greatest importance (Haass and Selkoe, 2007) (for potential functions of APP processing products, see Figure 1B ).
Only aggregated or oligomeric Ab, but not the monomeric Ab, is neurotoxic and causes neuronal hyperactivity within the neighborhood of amyloid plaques (Busche et al., 2008) , an activity that is normalized by anti-amyloid vaccination and b-secretase inhibition in APP transgenic mouse models (Zott et al., 2018) . In parallel, oligomeric forms of Ab lower long-term potentiation (LTP) in organotypic slices. Thus, disruption of the delicate balance of excitation and inhibition within neuronal circuits may be the basis of Ab-driven dysfunctions in AD (Zott et al., 2018) . In contrast to Ab, p3 does not form oligomers and appears to be benign. Ah-a blocks neuronal activity and acts in exactly the opposite way as oligomeric Ab, whereas Ah-b apparently does not affect neuronal activity (Willem et al., 2015) .
What about the different sAPP variants? Obviously, the most abundant species, sAPP-a, was already in the center of major screening efforts for a potential receptor. The M€ uller lab identified the postsynaptic a7 nicotinic acetylcholine receptor (nAChR) as a selective sAPP-a binding protein (Richter et al., 2018) (for potential receptors of APP processing products, see Figure 1B ). Binding of sAPP-a to the nAChR is a high-affinity interaction with an EC 50 of 10.7 nM. sAPP-b does not interact with the nAChR and its receptor remained enigmatic. Consistent with these findings, the last 16 amino acids of sAPP-a, which are missing in the truncated sAPP-b ( Figure 1A ) were found to be required and sufficient for the interaction. Since these 16 amino acids are also part of Ah-a, it is tempting to speculate that this peptide may also bind to the nAChRs. sAPP-a, but not sAPP-b, was shown to rescue deficits in hippocampal LTP, which were observed in APP knockout mice (Hick et al., 2015) . This suggested that increasing sAPP-a over a long time period may be therapeutically beneficial for AD patients.
However, to make things more complicated, an additional sAPP receptor with a completely different function may now come into play. Rice et al. present GABA B R1 as a novel candidate for a sAPP receptor in a recent publication in Science (Rice et al., 2019) . Using a fairly simple approach to identify putative receptors, they generated recombinant sAPP fused to a C-terminal IgG-Fc-tag to pull down candidate binding partners from synaptosomal preparations. A surprisingly small number of binding partners was precipitated, among them g-aminobutyric acid type B receptor subunit 1 (GABA B R1). GABA B receptors are G-protein-coupled proteins interacting with g-aminobutyric acid (GABA), the predominant inhibitory neurotransmitter of the brain. GABA B R1was pulled down by both sAPP-a and sAPP-b. GABA B R1 exists in two variants (GABA B R1a and GABA B R1b), where only the 1a variant contains sushi repeats (Vigot et al., 2006) . In HEK293 cells, Rice et al. (2019) could show that only the sushi domain containing GABA B variant bound sAPP. In support of these findings, excess amounts of a recombinant sushi peptide competed for sAPP binding. Isothermal titration calorimetry (ITC) determined the dissociation constant for the sAPP-a/ sushi interaction to be 431 nM, which appears quite high and suggests a rather low-affinity interaction. Within APP, the binding domain could be restricted to the extension domain (ExD), and in support of this, deletion of the ExD prevented binding. Furthermore, all three major types of sAPP introduced above (sAPP-a, sAPP-b, and sAPP-h) contain the ExD (see Figure 1A) and consequently bound to cell-surface-expressed GABA B R1a, which is very much in contrast with the selective binding of only sAPP-a to nAchR. Importantly, the two APP homologs, APLP1 and APLP2, which lack the ExD but also undergo a-secretory processing, failed to bind to GABA B R1a. The binding region within the ExD could be narrowed down to an evolutionary conserved 17 amino acid stretch. This small peptide was not only sufficient to selectively bind to the sushi domain of GABA B R1a, but also converted the naturally unfolded sushi domain to a stable structure.
Whereas all binding assays were performed in HEK293 cells or in vitro but not in neurons, compelling functional assays were performed in cultured hippocampal neurons. Here, Rice et al. (2019) investigated whether sAPP can modulate neuronal function. Strikingly, it was observed that both sAPP-a and sAPP-b, but not the recombinant ectodomains of APLP1 or APLP2, reduced the frequency of excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs, respectively). In support of their binding data, this activity was dependent on the presence of the APP-specific ExD. Similar results were found when Rice et al. (2019) sAPP-a were used in these experiments, and one should note that the in vivo concentrations of sAPP-a as measured within the interstitial fluid are around 1 nM (Dobrowolska et al., 2014) . To demonstrate an in vivo activity of sAPP on GABA B R1mediated modulation of neuronal activity, Rice et al. (2019) measured calcium transients of CA1 hippocampal neurons by two-photon imaging in living mice. This demonstrated that the 17-mer peptide of the ExD reduced the frequency of calcium transients although again only when rather high concentrations of 5 mM were used. This set of data needs, however, to be extended with the naturally occurring sAPP variants expressed over extended time periods. In addition, Rice et al. (2019) focus only on presynaptic functions of the 17-mer peptide, but GABA B R1 is also expressed on the postsynaptic site. From this large and comprehensive set of in vitro and in vivo experiments, Rice et al. (2019) conclude that sAPP variants containing the ExD inhibit neuronal activity via binding to the sushi domain of GABA B R1. In future work, these findings could be further strengthened in a GABA B R1 knockout, which should prevent modulation of neuronal activity by sAPP or the 17-mer peptide. Furthermore, similar experiments should be conducted by endogenously deleting the ExD of APP. Such a mouse mutant should then be compared to mice lacking the last 16 amino acids of sAPP-a, which are, as described above, required for the interaction with the nAChR. The identification of GABA B R1 and nAChR as the interaction partners of sAPP make it very difficult to predict how promising any therapeutic strategy via enhancing of sAPP expression may be. It has been shown that increased levels of sAPP-a rescue LTP deficits in an APP knockout (Hick et al., 2015) , yet the new data complicate this picture. sAPP interaction with the GABA B R1 dampens neuronal activity. One may therefore speculate that sAPP-a could reduce the local hyperactivity of neurons in the vicinity of amyloid plaques (Busche et al., 2008) . This suggests that the different cleavage products of APP are part of a well-balanced network to maintain brain homeostasis via differential interaction of cleavage products with different neuronal receptors. Any interference with individual players of this regulatory network may thus have deleterious consequences. Moreover, one may even speculate that b-secretase inhibitors may lead to an imbalance of APP-mediated modulation of neuronal activity, and clinical trials may therefore have been deleterious. Indeed, as mentioned above, inhibition of b-secretase increases Ah-a (Willem et al., 2015) , an APP-derived peptide, which blocks neuronal activity, and simultaneously increases sAPP-a generation. Both proteins together may even lead to an enhanced suppression of neuronal activity. Thus, any interference with the rather delicate balance of APP processing may be counterproductive for therapeutic efforts, and very careful studies are required to validate the therapeutic value of secretase inhibitors.
